After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s GHRS Investigational New Drug (IND) application...
The former leader of Operation Warp Speed’s vaccines effort, which led to a quick rollout of Covid jabs, is getting federal funding for his biotech’s...
CraniUS, a medtech company based in Baltimore, has developed the NeuroPASS drug delivery system. The technology is designed to deliver drugs to the brain,...
Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This...
A top UVA Health cancer expert is highlighting how a new drug could transform how doctors treat a brain tumor that typically strikes younger people. Credit:...
When Sernova announced in June that five patients with type 1 diabetes with severe hyperglycemia and a complete inability to produce insulin were able...
Yet Another Fear-Mongering COVID Surge Turns Into Trickle As Hospital Admissions Wane Authored by Jack Phillips via The Epoch Times (emphasis...
Joe Arron and Mark Eisner worked together for about a decade at Genentech, with broad remits but a shared passion for interstitial lung disease. They’d...
Altesa BioSciences has raised a $35 million Series A from undisclosed investors, according to an SEC filing from July. The company develops antiviral drugs...
The FDA has approved a subcutaneous version of Takeda’s ulcerative colitis drug Entyvio, more than three years after rejecting the company’s application...
A research team led by Shuilin Wu at Tianjin University, China, has made a groundbreaking discovery in the field of intelligent catalysis. Their research...
The FDA on Thursday approved Amicus Therapeutics’ combo therapy for a rare inherited lysosomal disorder called Pompe disease following several regulatory...
Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly...
Buzz on the Bullboards: Markets underperforming, or is the best yet to come? The September rally didn’t pan out as indices hit lows. The post Buzz...
Harbinger Health, a startup with ambitious goals to develop liquid biopsies that spot signs of cancer early, has raised $140 million in Series B funding...
Pharmaceutical drug developer PharmaTher Holdings further advanced its ketamine-based medical product ambitions with a noteworthy announcement today. The...
Femasys Inc. (NASDAQ: FEMY) hit a massive milestone and saw shares soar by a whopping 346%. The reason? The United States Food and Drug Administration...
Yale University and Transcend Therapeutics, a rapid-acting psychedelic therapies developer, received a three-year collaborative grant from the U.S....
Following quickly on the heels of US biosimilar approvals, Amsterdam-based Polpharma Biologics scored a European Commission authorization for its Tysabri...
The Dales Report is here with another Psychedelic Exclusive podcast. Today, Shadd and Anthony sit down with analyst Elmer Piros to talk about the investment...
OAK BROOK, Ill. – In a study of more than 2,000 chest X-rays, radiologists outperformed AI in accurately identifying the presence and absence of three...
A lot of news action could happen in cannabis this week, between actions in Washington DC, and Benzinga’s Cannabis Capital Conference taking place September...
Ionis is another step closer to the launch of its first independent drug, touting positive Phase III data for olezarsen in patients with a rare genetic...
By not disclosing milestone dollars that may or may never materialize, Exelixis showed Insilico Medicine CEO Alex Zhavoronkov, PhD, that its PR folks were...
Takeda is betting more than half a billion dollars on a California biotech’s approach to treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative...
The Dales Report is here with another Psychedelic Exclusive podcast. Today, Shadd and Anthony sit down with analyst Elmer Puro to talk about the investment...
Psychedelics are one of the buzziest topics in tech these days. With entrepreneurs vouching for their benefits for creativity, focus and general well-being...
CDC Refuses To Release Updated Information On Post-COVID Vaccination Heart Inflammation Authored by Zachary Stieber via The Epoch Times, The...
COVID-19 Virus Levels In Wastewater Have Dropped Authored by Naveen Athrappully via The Epoch Times (emphasis ours), Wastewater COVID levels...
As Karuna Therapeutics wraps up its FDA approval request for what could be the first new type of schizophrenia drug in decades, another East Coast biotech...